CXCR4 and acute myeloid leukemia: In addition, a number of small peptide CXCR4 antagonists have been studied in preclinical mouse models and have shown similar chemosensitizing effects through a variety of pathways including mobilization of AML cells into the peripheral blood [20], activation of pro-apoptotic pathways [21, 22], or inhibition of proliferation [20].